Risk Factors for Glaucoma Diagnosis and Surgical Intervention following Pediatric Cataract Surgery in the IRIS® Registry

Vu, Daniel M.; Elze, Tobias; Miller, Joan W.; Lorch, Alice C.; VanderVeen, Deborah K.; Oke, Isdin; Pershing, Suzann; Hyman, Leslie; Haller, Julia A.; Lee, Aaron Y.; Lee, Cecilia S.; Lum, Flora; Miller, Joan W.; Lorch, Alice C.

doi:10.1016/j.ogla.2023.08.009

Cited by 1 publication

(3 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Secondary glaucoma has been reported in 6% to 75.9% of children following congenital cataract surgery [1][2][3][4][5][6][7]. The incidence varies according to the criteria used in the studies [8].…”

Section: Introductionmentioning

confidence: 99%

“…More than half of the eyes in published studies required two or more sequential surgical interventions [8]. Trabeculectomy, angle surgery, cyclodestructive laser treatment, and drainage implants are among the surgical treatments employed in these cases [3,4,[7][8][9]. However, the insertion of a glaucoma drainage device (GDD) has shown better long-term control of IOP and tends to be the preferred technique over trabeculectomy [4,[8][9][10][11][12].…”

Section: Introductionmentioning

confidence: 99%

“…Trabeculectomy, angle surgery, cyclodestructive laser treatment, and drainage implants are among the surgical treatments employed in these cases [3,4,[7][8][9]. However, the insertion of a glaucoma drainage device (GDD) has shown better long-term control of IOP and tends to be the preferred technique over trabeculectomy [4,[8][9][10][11][12]. The Ahmed Glaucoma Valve is the most common GDD used in pediatric GFCS [8,11,13].…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Paul Glaucoma Implant following Congenital Cataract Surgery in a Pediatric Cohort

Mendoza-Moreira,

Voigt,

Stingl

et al. 2024

JCM

View full text Add to dashboard Cite

Background: The aim of this study was to evaluate the short-term efficacy and safety of the Paul Glaucoma Implant (PGI) in pediatric eyes diagnosed with glaucoma following congenital cataract surgery (GFCS). Methods: A retrospective, single-center, descriptive study was conducted on consecutive children diagnosed with GFCS who underwent PGI implantation between July 2022 and November 2023 at the University Medical Center Mainz. The primary outcome measure was the reduction in IOP at the last follow-up visit. Results: Ten eyes of nine children were included in the study. The mean follow-up time was 7.70 ± 4.22 months (4.68–10.72 months). At the end of the study follow-up, the mean (95% CI) reduction in IOP was −14.8 ± 8.73 mmHg (−8.56 to −21.04 mmHg, p < 0.001). At the last follow-up, 30.0% (3/10) of patients achieved an IOP (intraocular pressure) of ≥6 and ≤21 mmHg with a reduction in IOP of ≥25% without treatment, while 90.0% (9/10) achieved this target IOP regardless of glaucoma medication treatment. The mean number of antiglaucoma medications was significantly reduced from 3.50 (IQR = 1) to 2.0 (IQR = 2, p = 0.01), and the visual acuity logMAR improved from 1.26 ± 0.62 to 1.03 ± 0.48 (p = 0.04). Only one eye experienced numerical hypotony (4 mmHg) without choroidal detachment or anterior chamber shallowing within the first 24 h. No other adverse events were observed during the follow-up period. Conclusions: PGI implantation significantly lowered IOP and the number of antiglaucoma eye drops with a favorable safety profile in children diagnosed with GFCS, thereby achieving a high rate of qualified surgical success in the short term.

show abstract